How Vitamin D Uses Cathelicidin to Protect Against Ulcerative Colitis

Vitamin D's protective effects in ulcerative colitis (UC) appear to work through cathelicidin, an antimicrobial peptide. In UC patients, higher vitamin D levels correlated with higher cathelicidin levels in both blood and colon tissue, and higher serum cathelicidin was associated with decreased risk of histologic inflammation and clinical relapse. In lab experiments, vitamin D treatment of human colon cells induced cathelicidin production and the anti-inflammatory cytokine IL-10, suppressed the pro-inflammatory cytokine TNF-α, and killed E. coli bacteria — an antimicrobial effect that disappeared when cathelicidin was knocked down. In mice, rectal cathelicidin administration reduced the severity of chemically induced colitis.

A multi-part study: (1) Measured serum and colonic cathelicidin levels in UC patients and correlated them with clinical outcomes. (2) Treated human colon epithelial cells with active vitamin D and measured cathelicidin, cytokines (IL-10, TNF-α), and antimicrobial activity against E. coli, with siRNA knockdown to confirm cathelicidin's role. (3) Administered intrarectal cathelicidin to mice with DSS-induced colitis and assessed disease severity and gut microbiota changes.

Vitamin D supplementation has long been associated with better outcomes in inflammatory bowel disease, but the mechanism was unclear. This study identifies cathelicidin as a key mediator — vitamin D triggers colon cells to produce this antimicrobial peptide, which then fights harmful bacteria and reduces inflammation. This opens the possibility of directly targeting the vitamin D-cathelicidin pathway as a treatment for UC.

This study connects two well-known areas of research — vitamin D in IBD and antimicrobial peptides in gut defense — by showing cathelicidin is the link between them. It adds to growing evidence that the innate immune system's antimicrobial peptides play a central role in maintaining gut health, and suggests that boosting cathelicidin production (whether through vitamin D or directly) could become a therapeutic strategy for inflammatory bowel disease.

The correlation between cathelicidin and reduced inflammation in UC patients was not independent of vitamin D levels or baseline inflammation, making it difficult to separate cathelicidin's independent effect. The mouse model used chemically induced colitis, which differs from human UC. Intrarectal cathelicidin reduced colitis severity but did not reverse the changes in gut microbiota composition caused by colitis.